To demonstrate the value of this system in chemotherapeutic drug screening, tumor organoids have been treated with epithelial growth factor receptor (EGFR)-inhibitors, which reduce tumor growth only in GBM organoids overexpressing EGFR [50]. This evidence concerns the gene EGFR and glioblastoma.